MENLO PARK, Calif., May 1, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will release its first quarter financials after the market close on May 8, 2012 and that it will be presenting at the 11th Annual JMP Research Conference in San Francisco, California.
The Company will hold a conference call at 5:00 pm EDT (2:00 pm California time) regarding the first quarter financials. The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. The dial-in number for the conference call is 877-856-1964 and the passcode is 646617. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A recording of webcast will be available on the Company's website for 30 days.
The presentation at the JMP conference is scheduled for 12:30 pm EDT (9:30 am California time) on Monday May 14, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be on the Company's website for 30 days.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529